Goldman Sachs Group Inc. Boosts Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Goldman Sachs Group Inc. grew its position in Ascendis Pharma A/S (NASDAQ:ASND) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 422,854 shares of the biotechnology company’s stock after purchasing an additional 12,881 shares during the period. Goldman Sachs Group Inc. owned approximately 0.73% of Ascendis Pharma A/S worth $53,258,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Vestal Point Capital LP acquired a new position in Ascendis Pharma A/S in the 4th quarter worth approximately $78,719,000. Massachusetts Financial Services Co. MA increased its stake in shares of Ascendis Pharma A/S by 20.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock worth $191,346,000 after acquiring an additional 254,749 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of Ascendis Pharma A/S by 6.0% during the fourth quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock worth $507,658,000 after purchasing an additional 228,457 shares during the last quarter. First Turn Management LLC acquired a new position in Ascendis Pharma A/S during the fourth quarter valued at $19,092,000. Finally, abrdn plc purchased a new stake in Ascendis Pharma A/S in the fourth quarter valued at $17,481,000.

Ascendis Pharma A/S Stock Down 1.1 %

Shares of NASDAQ ASND opened at $123.19 on Wednesday. The firm has a market cap of $7.17 billion, a price-to-earnings ratio of -12.82 and a beta of 0.59. The company’s 50-day simple moving average is $134.71 and its 200-day simple moving average is $136.68. Ascendis Pharma A/S has a 52-week low of $85.08 and a 52-week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. The firm had revenue of $103.11 million during the quarter, compared to analyst estimates of $85.72 million. Equities research analysts anticipate that Ascendis Pharma A/S will post -5.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Morgan Stanley upped their price objective on Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 16th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, May 23rd. Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $179.44.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.